PRINCETON, N.J., Nov. 15, 2017 /PRNewswire/ -- Promius Pharma LLC announced today that ZEMBRACE ® SymTouch ® (sumatriptan injection) 3 mg, an acute migraine headache treatment on the market since ...
Tosymra Nasal Spray 10 mg is a Proprietary Acute Migraine Treatment Approved Under the 505(b)2 Pathway Based on Bioequivalence to Imitrex (sumatriptan) Injection 4 mg GlaxoSmithKline Recently Notified ...
Sumatriptan 5mg, 20mg; per spray. The vascular 5-HT 1 receptor subtype to which sumatriptan binds selectively, and through which it presumably exerts its antimigrainous effect, is present on cranial ...
Dr. Reddy's Laboratories (NYSE: RDY), announced today that the U.S. Food and Drug Administration (FDA) has approved ZEMBRACE™SymTouch™ (sumatriptan succinate) injection, a drug-device combination ...
Imitrex is available as a generic drug. The maximum single recommended adult dose of Imitrex Injection for the acute treatment of migraine or cluster headache is 6 mg injected subcutaneously. For the ...
Tosymra (sumatriptan) is a prescription drug used to treat migraine. The drug comes as a nasal spray. You usually use a single dose, which may be repeated two more times in a 24-hour period if needed.
Nov 13 (Reuters) - Drugmaker Spectrum Pharmaceuticals Inc. on Monday said it settled a patent suit with GlaxoSmithKline relating to the UK-based company's migraine injection, Imitrex. Under the terms, ...
Dec 21 (Reuters) - Spectrum Pharmaceuticals Inc. said the U.S. District Court at its request has dismissed the patent litigation with GlaxoSmithKline , allowing it to move forward under the settlement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results